Lisata Therapeutics
LSTA
35 hedge funds and large institutions have $7.09M invested in Lisata Therapeutics in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
1,778% more capital inflows, than outflows
Capital inflows: $4.57M | Capital outflows: $243K
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
40% more funds holding
Funds holding: 25 → 35 (+10)
7.64% more ownership
Funds ownership: 8.11% → 15.75% (+7.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deeter Investments
Austin,
Texas
|
+$1.5M |
| 2 |
Deltec Asset Management
New York
|
+$372K |
| 3 |
Rangeley Capital
New Canaan,
Connecticut
|
+$310K |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
+$256K |
| 5 |
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
+$196K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$136K |
| 2 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$72.5K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$26.5K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$7.29K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$268 |
LSTA Hedge Fund Activity: Q1 2026 in Review
35 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2026, worth a combined $7.09M — up 423% from $1.36M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LSTA positions and 4 closed out — a net gain of 11 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Deeter Investments, opening a new position worth an estimated $1.5M. The largest seller was BML Capital Management, exiting entirely with an estimated $136K sold.
- 35 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2026, up from 25 in Q4 2025.
- Funds reported $7.09M of Lisata Therapeutics stock for Q1 2026, up 423% quarter-over-quarter.
- 15 funds opened new Lisata Therapeutics positions in Q1 2026 and 4 closed out, a net change of +11 holders.
- The largest Lisata Therapeutics buyer in Q1 2026 was Deeter Investments, an estimated $1.5M added.
- The largest Lisata Therapeutics seller in Q1 2026 was BML Capital Management, an estimated $136K sold.
Based on aggregated 13F filings for Q1 2026.